IMTX — Immatics N.V.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1809196 ·
Last close
$8.37
Market Cap
$1.27B
52W High
$12.41
52W Low
$7.10
ADV30
671,090
Next earnings
2026-11-17
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 9,144,000 | — | -67,204,000 | -62,492,000 | 485,735,000 | 232,459,000 | 86,110,000 |
| Mar 2026 | 7,612,000 | — | -66,064,000 | -57,814,000 | 543,264,000 | 301,332,000 | 87,463,000 |
| Dec 2025 | 19,761,000 | — | -38,881,000 | -35,698,000 | 562,337,000 | 345,918,000 | 78,238,000 |
| Sep 2025 | 5,187,000 | — | -54,633,000 | -50,545,000 | 518,557,000 | 334,922,000 | 101,878,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-184,463,000
Investing CF
$129,895,000
Financing CF
$119,061,000
CapEx
$-4,433,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.76
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-843,802,000
Inventory
—
Receivables
$4,815,000
ST Investments
$152,238,000
EBIT TTM
$-214,438,000
Pretax Income TTM
$-215,347,000
Interest Exp TTM
$909,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$41,704,000
EBITDA
$-218,028,992
Free Cash Flow
$-126,542,624
Enterprise Value
$822,760,896
Total Cash
$393,350,016
Total Debt
$14,606,000
Shares Out
152,225,077
Trailing EPS
$-1.85
Book Value
$3.39
ROE
-47.8%
ROA
-26.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 48,266,000 | -182,016,000 | -196,447,000 | 562,337,000 | 78,238,000 | 484,099,000 | -176,626,000 |
| Dec 2024 | 155,835,000 | -38,615,000 | 15,218,000 | 696,146,000 | 121,304,000 | 574,842,000 | -158,030,000 |
| Dec 2023 | 53,997,000 | -101,725,000 | -94,649,000 | 509,965,000 | 292,347,000 | 217,618,000 | 18,228,000 |
| Dec 2022 | 172,831,000 | 29,954,000 | 27,703,000 | 407,820,000 | 204,467,000 | 203,353,000 | 100,131,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.07
Max Pain — expiry 2026-10-16
max pain strike: $9.00 · spot: $8.37 · call oi: 1,271 · put oi: 212Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| REPL | Replimune Group, Inc. | $1.16B | $12.36 | — |
| MAZE | Maze Therapeutics, Inc. | $1.45B | $26.05 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.47B | $99.61 | — |
| VOR | Vor Biopharma Inc. | $1.10B | $18.52 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.52B | $4.67 | — |
News headlines (Yahoo Finance, 1h cache)
Immatics and 4 More Stocks See Action From Activist Investors
2026-09-04 22:59 · Yahoo
Immatics Announces $150 Million Underwritten Offering
2026-08-25 11:00 · Yahoo
Immatics Announces Second Quarter 2026 Financial Results and Business Update
2026-08-18 11:00 · Yahoo
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
2026-06-01 12:00 · Yahoo
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
2026-05-31 13:00 · Yahoo
Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results
2026-05-15 10:59 · Yahoo
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-12 12:25 · Yahoo
Immatics Announces First Quarter 2026 Financial Results and Business Update
2026-05-12 11:00 · Yahoo
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
2026-05-06 16:00 · Yahoo
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
2026-04-21 14:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.